AARP Responds to First 10 Medicare Part D Drugs Selected for Historic Negotiation
AARP Responds to First 10 Medicare Part D Drugs Selected for Historic Negotiation En español | WASHINGTON— AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services’ list of the first 10 drugs to be negotiated for lower prices by Medicare: […]
New Report: Top Medicare Part D Drugs Have More Than Tripled in Price Since Entering Market
New Report: Top Medicare Part D Drugs Have More Than Tripled in Price Since Entering Market En español | WASHINGTON — List prices for the 25 brand-name drugs with the highest total Medicare Part D spending in 2021 have increased by an average of 226%—or more than tripled—since they first entered the market, a new report […]